Cardiovascular Disease Management

Patient Risk Assessment

• Patients aged ≥65 years are considered high risk by the American College of Cardiology 1
• A 10-year ASCVD risk score ≥7.5% is the threshold for moderate-to-high intensity statin therapy, according to the American College of Cardiology 2, 1
• Age is a factor in statin therapy, with patients aged 66 years benefiting significantly from statin therapy for primary prevention, as recommended by the American College of Cardiology 2, 1
• African American ethnicity is considered a high-risk ethnic group by the American College of Cardiology 1

Statin Therapy Recommendations

• High-intensity statin therapy is recommended to reduce cardiovascular events in high-risk patients, with a reduction in LDL-C by ≥50%, according to the American College of Cardiology 2, 3
• Monitoring liver function tests at baseline and as clinically indicated is recommended for patients on statin therapy by the American College of Cardiology 2
• High-intensity statins may increase the risk of new-onset diabetes, with approximately 0.3 excess cases per 100 patients per year, as noted by the American College of Cardiology 2
• Alternative high-intensity statins, such as rosuvastatin 20-40 mg, should be considered if patients cannot tolerate high-intensity atorvastatin, according to the American College of Cardiology 3
• Ezetimibe should be added if LDL-C remains elevated despite maximally tolerated statin therapy, as recommended by the American College of Cardiology 1
• The following statin doses and intensities are recommended:

4, 3

Special Considerations

• Caution is recommended when using high-intensity statins in patients aged >75 years, but benefits clearly outweigh risks for patients aged 66 years, according to the American College of Cardiology 2, 1
• African American patients may respond similarly to statin therapy as other ethnic groups, as noted by the American College of Cardiology 2
• A stepwise titration approach is recommended for increasing atorvastatin from 10 mg to 80 mg, with monitoring at 4-week intervals, rather than an immediate increase to the maximum dose, in patients with established ASCVD, LDL-C requiring >45% reduction, or very high-risk patients, according to the American College of Cardiology 3
• High-intensity statin therapy (80 mg) is associated with a higher risk of side effects compared to moderate-intensity therapy (10-20 mg), with a risk of myopathy increasing with higher doses, approximately 2 excess cases per 1,000 individuals treated for 1 year with high-intensity vs. moderate-intensity statins, as noted by the American College of Cardiology 2, 3
• Faster titration or direct escalation to 80 mg may be considered in very high-risk patients with recent acute coronary syndrome or patients requiring >45% LDL-C reduction who have previously tolerated moderate-intensity statin therapy, according to the American College of Cardiology 2
• Dose titration should not proceed if ALT/AST >3 times upper limit of normal, significant muscle symptoms develop, CK >10 times upper limit of normal, or intolerable side effects occur, as recommended by the American College of Cardiology 2, 3
• The American Heart Association recommends the following LDL-C reductions with atorvastatin: 10 mg (approximately 39% reduction), 20 mg (approximately 43% reduction), 40 mg (approximately 48% reduction), and 80 mg (approximately 51-55% reduction) 3
• Specific atorvastatin doses should not be exceeded with certain medications: Clarithromycin or itraconazole (maximum 20 mg daily), Amiodarone (maximum 80 mg daily, but monitor closely), and HIV protease inhibitors (maximum 20-40 mg daily, depending on specific agent) 5

Lifestyle Modifications and Additional Therapies

• Dietary patterns rich in vegetables, fruits, whole grains, low-fat protein sources, and healthy oils are recommended by the American College of Cardiology and American Heart Association 1
• Lifestyle modifications (diet, exercise, weight loss) should be emphasized alongside statin therapy, as recommended by the American Heart Association 6
• Statins should complement, not replace, lifestyle interventions for both cardiovascular risk and diabetes prevention, according to the American Heart Association 6
• Adding ezetimibe for patients not reaching goals on maximally tolerated statin therapy, with consideration for further intensification if needed, is recommended by the European Heart Journal and American College of Cardiology 7, 8
• Adding non-statin agents, such as ezetimibe, to statin therapy can provide additional LDL-C reduction when statin therapy is insufficient, as recommended by the American College of Cardiology 9, 10

Patient Categories and Recommended Statin Intensities

• The following patient categories and recommended statin intensities are suggested:

• The American Diabetes Association recommends continuing statin treatment for patients aged >75 years already on statin therapy, and considering initiation of moderate-intensity statin therapy for patients aged >75 years not on statin therapy after discussion of potential benefits and risks 13
• The American College of Cardiology recommends high-intensity statin therapy for patients with established atherosclerotic cardiovascular disease (ASCVD) to reduce LDL cholesterol by ≥50% from baseline 14, 13
• For patients with diabetes aged 40-75 years with additional ASCVD risk factors, high-intensity statin therapy is considered reasonable by the American College of Cardiology and the American Diabetes Association 14, 13